GlaxoSmithKline will pay $92 million to resolve class-action lawsuits alleging that it attempted to monopolize the market for its antibiotic Augmentin by preventing the entry of generic competitors. The lawsuits were filed by consumers, health plans and pharmaceutical wholesalers in 2002 in U.S. District Court, Alexandria, Va. GlaxoSmithKline settled without admitting guilt. It said it would take a second-quarter charge of $314.9 million for the settlement and other legal costs. The company faces similar lawsuits involving other drugs that it markets. -- by Mark Taylor
GlaxoSmithKline to pay $92 million settlement
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.